Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cipher reports Q2 2010 financial results


      News provided by

      Cipher Pharmaceuticals Inc.

      Jul 28, 2010, 07:00 ET

      Share this article

      Share this article


      Toronto Stock Exchange Symbol: DND

      MISSISSAUGA, ON, July 28 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2010.

          
          Q2 2010 Summary
          ---------------
      
          -   Net revenue increased to $2.2 million from $0.7 million in Q2 2009,
              driven mainly by the achievement of a US$1 million commercial
              milestone for Lipofen(R).
          -   Net income for the quarter was $0.7 million, or $0.03 per share,
              compared with a loss of $0.8 million, or $0.03 per share, for
              Q2 2009.
          -   Achieved final FDA approval for CIP-TRAMADOL ER, the Company's
              extended-release tramadol product.
          -   Reached 75% enrolment (over 700 patients) in CIP-ISOTRETINOIN
              Phase III safety study.
          -   Strong balance sheet at quarter end with cash of $10.3 million and no
              debt, compared with cash of $9.0 million at December 31, 2009.
          
      

      "The second quarter was highlighted by final FDA approval of our extended-release tramadol - our second product approved in the U.S. market," said Larry Andrews, President and CEO of Cipher. "We are working diligently to finalize a marketing partnership as we prepare for commercial launch, targeted for the first quarter of 2011. Achievement of a sales milestone for Lipofen(R) during the quarter reflects Kowa's continued commercial success in the U.S. and further strengthens our financial position."

          
          Financial Review
          ----------------
          
      

      Net revenue in Q2 2010 was $2.2 million, compared with $0.7 million in Q2 2009. The improved performance reflects a continuing trend of higher royalty revenue for the product during the quarter, as well as the achievement of a one-time US$1 million commercial milestone for Lipofen(R).

      Gross Research and Development ("R&D") expenditures for Q2 2010 rose to $3.5 million, compared with $1.5 million in Q2 2009, driven by the CIP-ISOTRETINOIN clinical study. The reported R&D expenditure amount of $0.2 million for Q2 2010 is net of $3.3 million of reimbursed expenses by Cipher's U.S. marketing partner. Operating, General and Administrative ("OG&A") expenses for Q2 2010 were $1.1 million, consistent with the prior year.

      For the three months ended June 30, 2010, the Company recorded net income of $0.7 million ($0.03 per basic and diluted share), compared with a loss of $0.8 million ($0.03 per basic and diluted share) for Q2 2009.

      For the first half of 2010, the Company recorded net revenue of $3.1 million, compared with $1.3 million in the first half of 2009. Net income for the first six months of 2010 was $0.2 million ($0.01 per basic and diluted share), compared with a net loss of $1.6 million ($0.06 per basic and diluted share) in the first half of 2009.

      The Company's financial position remained solid at quarter-end. As at June 30, 2010, Cipher had cash of $10.3 million, compared with $9.0 million as at December 31, 2009 and continued to have no debt.

          
          Product Update
          --------------
          
      

      During Q2 2010, Lipofen(R) monthly prescriptions showed steady growth, as Kowa increased coverage of the primary care physicians in its targeted regions and expands its sales force. Kowa's sales force grew to approximately 250 at the end of the second quarter to support the recent launch of its pitavastatin product, LIVALO(R).

      During Q3 2009, Cipher commenced its Phase III safety trial for CIP-ISOTRETINOIN under a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA"). The 800-patient study is a double-blind, randomized trial comparing CIP-ISOTRETINOIN to an FDA-approved, commercially available isotretinoin product. The study is being conducted in the U.S. and Canada over an 18-month period. The study is progressing well with enrolment having reached more than 700 patients at the end of Q2 2010. The Company is expecting to complete enrolment toward the end of Q3 2010.

      In May 2010, Cipher announced that the FDA has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. Also during Q2 2010, the United States Court of Appeals upheld the lower court's original decision on patent infringement litigation initiated by Pharma Products L.P against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER, the reference product in Cipher's New Drug Application for CIP-TRAMADOL ER. This affirmed the invalidity of the asserted claims of the Orange Book-listed patents for Ultram(R) ER. These are the same patents that were originally asserted against Cipher and for which Cipher was granted summary judgment in January 2010. This decision confirms Cipher's long-held view that these patents are invalid, and further mitigates any remaining risk of patent litigation on these patents against CIP-TRAMADOL ER. Cipher is currently preparing for the U.S. commercial launch of the product, which includes securing a marketing partner and finalizing commercial manufacturing requirements. The Company is targeting Q1 2011 for commercial launch.

      Cipher continues to actively pursue new early stage pipeline product candidates and advance out-licensing discussions for its current products.

          
          Conference Call and Webcast
          ---------------------------
          
      

      Cipher will hold a conference call today, July 28, 2010, at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. A live audio webcast of the call will be available at www.cipherpharma.com. The webcast will be archived for 90 days.

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (FDA approval in May 2010) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

      Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.

      Forward-Looking Statements

      Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company's pipeline; changes in government regulation or regulatory approval processes; government and third-party payer reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

          
                               Cipher Pharmaceuticals Inc.
      
                             Unaudited Financial Statements
      
                         For the Three Months Ended June 30, 2010
      
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Balance Sheets
          (in thousands of dollars)
      
                                                                   As at
                                                            June 30,   December 31,
                                                             2010         2009
      
          ASSETS
      
          Current assets
          Cash and cash equivalents                       $    10,310  $     9,006
          Accounts receivable (note 2)                          2,851          967
          Prepaid expenses and other current assets               153          457
          Loan receivable (note 3)                                  -          800
          -------------------------------------------------------------------------
                                                               13,314       11,230
      
          Property and equipment, net                              72           86
      
          Intangible assets, net (note 4)                       3,490        3,507
      
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    16,876  $    14,823
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          LIABILITIES
      
          Current liabilities
          Accounts payable and accrued liabilities        $     2,784  $     1,570
          Current portion of deferred revenue                   1,405        1,956
          -------------------------------------------------------------------------
                                                                4,189        3,526
      
          Deferred revenue                                      1,224          329
          -------------------------------------------------------------------------
                                                                5,413        3,855
          -------------------------------------------------------------------------
      
          SHAREHOLDERS' EQUITY
      
          Share capital (note 5)                               49,977       49,948
          Contributed surplus (note 5)                         32,503       32,268
          Deficit                                             (71,017)     (71,248)
          -------------------------------------------------------------------------
                                                               11,463       10,968
          -------------------------------------------------------------------------
      
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    16,876  $    14,823
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Operations and Comprehensive Income
          (in thousands of dollars, except per share amounts)
      
                              For the three months ended  For the six months ended
                                          June 30                   June 30
                                     2010         2009         2010         2009
      
          Revenues
            Licensing revenue   $     2,218  $       678  $     3,136  $     1,280
          -------------------------------------------------------------------------
      
          Expenses
            Research and
             development                245          225          523          454
            Operating, general
             and
             administrative           1,052        1,057        2,020        2,046
            Amortization of
             property and
             equipment                   14           18           28           37
            Amortization of
             intangible
             assets                     176          189          352          377
            Interest income             (12)         (27)         (18)         (73)
          -------------------------------------------------------------------------
      
                                      1,475        1,462        2,905        2,841
          -------------------------------------------------------------------------
      
          Income (loss) and
           comprehensive
           income (loss)
           for the period       $       743  $      (784) $       231  $    (1,561)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          Basic and diluted
           earnings (loss)
           per share
           (note 6)             $      0.03  $     (0.03) $      0.01  $     (0.06)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Deficit
          (in thousands of dollars)
      
                              For the three months ended  For the six months ended
                                          June 30                   June 30
                                     2010         2009         2010         2009
      
          Deficit, beginning
           of period            $   (71,760) $   (69,310) $   (71,248) $   (68,533)
      
          Income (loss) for
           the period                   743         (784)         231       (1,561)
          -------------------------------------------------------------------------
      
          Deficit, end of
           period               $   (71,017) $   (70,094) $   (71,017) $   (70,094)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Unaudited Statements of Cash Flows
          (in thousands of dollars)
      
                              For the three months ended  For the six months ended
                                          June 30                   June 30
                                     2010         2009         2010         2009
      
          Cash provided by
           (used in)
      
          Operating activities
            Income (loss)       $       743  $      (784) $       231  $    (1,561)
            Items not affecting
             cash
              Amortization of
               property and
               equipment                 14           18           28           37
              Amortization of
               intangible
               assets                   176          189          352          377
              Stock-based
               compensation
               expense                  130          164          249          325
              Imputed interest            -          (19)           -          (47)
          -------------------------------------------------------------------------
                                      1,063         (432)         860         (869)
            Net change in
             non-cash
             operating
             items                      458          968          (22)         137
          -------------------------------------------------------------------------
      
                                      1,521          536          838         (732)
          -------------------------------------------------------------------------
      
          Investing activities
            Proceeds from loan
             receivable                   -            -          800          612
            Purchase of property
             and equipment              (13)          (5)         (14)          (5)
            Acquisition of
             intangible
             rights
             (note 4)                  (335)           -         (335)        (122)
          -------------------------------------------------------------------------
      
                                       (348)          (5)         451          485
          -------------------------------------------------------------------------
      
          Financing activities
            Proceeds from
             exercise of
             stock
             options
             (note 5)                    15            -           15            -
          -------------------------------------------------------------------------
      
          Increase (Decrease)
           in cash                    1,188          531        1,304         (247)
          Cash and cash
           equivalents,
           beginning of
           period                     9,122        9,103        9,006        9,881
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          Cash and cash
           equivalents,
           end of
           period               $    10,310  $     9,634  $    10,310  $     9,634
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          The accompanying notes are an integral part of these unaudited financial
          statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Notes to Unaudited Financial Statements
          June 30, 2010
          (in thousands of dollars, except per share amounts)
      
      
          1   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
      
              Basis of presentation
      
              The accompanying unaudited interim financial statements of the
              Company have been prepared in accordance with accounting principles
              generally accepted in Canada for interim reporting. Accordingly,
              these financial statements do not include all of the disclosures
              required by generally accepted accounting principles for annual
              financial statements and should be read in conjunction with the
              annual financial statements of the Company. In the opinion of
              management, all adjustments considered necessary for fair
              presentation have been included. All such adjustments are of a normal
              recurring nature. Operating results for the six months ended June 30,
              2010 are not necessarily indicative of the results that may be
              expected for the fiscal year ending December 31, 2010.
      
              There have been no changes to the accounting policies as described in
              Note 1 to the financial statements for the year ended December 31,
              2009.
      
          2   FOREIGN EXCHANGE FORWARD CONTRACT
      
              During the second quarter of 2010, the Company entered into a foreign
              exchange forward contract related to the net sales milestone of
              US$1 million under the Lipofen licensing and distribution agreement
              which was achieved at the end of the quarter. The contract matures on
              July 30, 2010 at an exchange rate of $1.031 against the US dollar.
              This foreign exchange forward contract is considered as an effective
              hedge to the US$1 million milestone and as such has been included in
              Accounts Receivable at the hedge rate.
      
          3   LOAN RECEIVABLE
      
              During the quarter ended March 31, 2010, the Company received the
              final instalment of $800 as part of the deferred payment agreement
              from the sale of Pharma Medica Research Inc. in February 2005.
      
          4   INTANGIBLE ASSETS
      
              The Company has entered into certain agreements with Galephar
              Pharmaceutical Research Inc. ("Galephar") for the rights to package,
              test, obtain regulatory approvals and market certain products in
              various countries around the world. In accordance with the terms of
              the agreements, the Company has acquired these intangible rights
              through an investment in three separate series of preferred shares of
              Galephar. The Company may be required to pay additional amounts to
              Galephar in respect of the CIP-ISOTRETINOIN and CIP-TRAMADOL ER
              intangible rights of up to $1,145 (US$1,080) if certain future
              milestones are achieved as defined in the agreements. These
              additional payments will be made in the form of additional Galephar
              preferred share purchases. The recovery of these intangible rights is
              dependant upon sufficient revenues being generated from the related
              products currently under development and commercialization. The
              Company is currently amortizing the intangible rights related to
              CIP-FENOFIBRATE and CIP-ISOTRETINOIN.
      
              CIP-FENOFIBRATE - in July 2007 the Company entered into a licensing
              and distribution agreement with Kowa Pharmaceuticals America, Inc.
              ("Kowa"), under which Kowa was granted the exclusive right to market,
              sell and distribute Lipofen in the United States. Lipofen was
              launched in the U.S. market in 2007. During the second quarter of
              2010, the Company reached a cumulative net sales level for the
              product that resulted in a contract milestone of US$1 million being
              achieved.
      
              CIP-ISOTRETINOIN - in August 2008, the Company entered into a
              development, distribution and supply agreement with Ranbaxy
              Pharmaceuticals Inc. ("Ranbaxy") under which Ranbaxy was granted the
              exclusive right to market, sell and distribute the product in the
              United States. To date, the Company has received an up-front
              licensing payment of US$1 million and a milestone payment of
              US$2 million as a result of reaching 50% of the patient enrolment
              level for the clinical trial. Under the terms of the the agreement
              the Company could receive additional pre- and post-commercialization
              milestone payments of up to US$21 million, based on the achievement
              of certain milestone targets. Once the product is commercialized, the
              Company will also receive a royalty based on a percentage of net
              sales. In addition, Ranbaxy will reimburse the Company for the costs
              associated with the clinical studies required by the FDA to secure
              NDA approval, up to a predetermined cap. Any additional development
              costs associated with initial FDA approval will be shared equally.
              The Company is responsible for all product development activities,
              including management of the clinical studies required by the FDA to
              secure NDA approval and is also responsible for product supply and
              manufacturing, which will be fulfilled by Galephar. After
              product-related expenses are deducted and after the recovery of
              Cipher's investment in the preferred shares of Galephar,
              approximately 50% of all milestone and royalties received by the
              Company under the agreement will be paid to Galephar.
      
              CIP-TRAMADOL ER - In May 2010, the Company received final approval
              from the FDA for its extended-release tramadol product for the
              treatment of moderate to moderately severe chronic pain in adults.
              The achievement of FDA approval triggers additional milestone
              payments to Galephar as the Company prepares for commercial
              manufacturing. During the second quarter of 2010 a payment of $335
              was made to acquire additional intangible rights for CIP-TRAMADOL ER.
      
          5   SHARE CAPITAL
      
              Authorized share capital
      
              The authorized share capital consists of an unlimited number of
              preference shares, issuable in series, and an unlimited number of
              voting common shares.
      
              Issued share capital
      
              The following is a summary of the changes in share capital from
              December 31, 2008 to June 30, 2010:
      
      
                                                            Number of
                                                          common shares     Amount
                                                          (in thousands)       $
      
              Balance outstanding - December 31, 2008
               and December 31, 2009                             24,055     49,948
                Options exercised during Q2 2010                     25         29
                                                          -------------------------
              Balance outstanding - June 30, 2010                24,080     49,977
                                                          -------------------------
                                                          -------------------------
      
      
              Stock option plan
      
              The following is a summary of the changes in the stock options
              outstanding from December 31, 2008 to June 30, 2010:
      
      
                                                                          Weighted
                                                              Number of    average
                                                               options    exercise
                                                                 (in        price
                                                              thousands)      $
      
              Balance outstanding - December 31, 2008             1,376       2.51
                Granted in 2009                                     224       0.60
                Expired in 2009                                     (20)      4.33
                                                          --------------
              Balance outstanding - December 31, 2009             1,580       2.22
      
                Granted during the three months ended
                 March 31, 2010 (a)                                 222       1.60
                Exercised during the three months
                 ended June 30, 2010 (b)                            (25)      0.61
                                                          --------------
              Balance outstanding - June 30, 2010                 1,777       2.17
                                                          --------------
                                                          --------------
      
      
              At June 30, 2010, 1,054,560 options were fully vested and exercisable
              (766,974 at June 30, 2009).
      
              (a) During the three months ended March 31, 2010, the Company issued
              221,500 stock options under the employee and director stock option
              plan, which have an exercise price of $1.60, 25% of which vest on
              February 19 of each year, commencing in 2011, and expire in 2020.
              Total compensation cost for these stock options is estimated to be
              $317. This cost will be recognized over the vesting period of the
              stock options.
      
              The stock options issued during the three months ended March 31, 2010
              were valued using the Black-Scholes option pricing model with the
              following assumptions:
      
                    Risk-free interest rate                       3.50%
                    Expected life                              10 years
                    Expected volatility                             97%
                    Expected dividend                               Nil
      
              (b) During the three months ended June 30, 2010, 25,000 stock options
              were exercised for a total cash consideration of $15. Capital stock
              increased by $29 representing the cash consideration of $15 and a $14
              reduction in contibuted surplus. No stock options were exercised in
              the three months ended June 30, 2009.
      
          6   EARNINGS PER SHARE
      
              Earnings per share is calculated using the weighted average number of
              shares outstanding. The weighted average number of shares outstanding
              for the three and six month periods ended June 30, 2010 was
              24,071,087 and 24,063,027 respectively (for both the three and six
              month periods ended June 30, 2009 the amount was 24,054,878). The
              dilutive impact on earnings per share for the three and six month
              periods ended June 30, 2010 is not significant.
      
              Basic and diluted loss per share for prior year comparative figures
              are the same because the exercise of stock options would have an
              anti-dilutive effect due to the net losses incurred in 2009.
          
      

      %SEDAR: 00020415E

      For further information: Craig Armitage, Investor Relations, The Equicom Group, (416) 815-0700 ext 278, (416) 815-0080 fax, [email protected]; Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext 324, (905) 602-0628 fax, [email protected]

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.